MM-129 as a Novel Inhibitor Targeting PI3K/AKT/mTOR and PD-L1 in Colorectal Cancer
Background and aims: The purpose of the present study was to examine the pharmacodynamics features of MM-129 (1,2,4-triazine derivative) as a novel promising drug candidate against colon cancer. Methods: MM-129 was assessed for antitumor activity through an in vivo study on Cby.Cg-Foxn1nu/cmdb mice....
Main Authors: | Justyna Magdalena Hermanowicz, Krystyna Pawlak, Beata Sieklucka, Robert Czarnomysy, Iwona Kwiatkowska, Adam Kazberuk, Arkadiusz Surazynski, Mariusz Mojzych, Dariusz Pawlak |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/13/3203 |
Similar Items
-
Assessment of an Anticancer Effect of the Simultaneous Administration of MM-129 and Indoximod in the Colorectal Cancer Model
by: Iwona Kwiatkowska, et al.
Published: (2023-12-01) -
Review of the Synthesis and Anticancer Properties of Pyrazolo[4,3-<i>e</i>][1,2,4]triazine Derivatives
by: Zofia Bernat, et al.
Published: (2020-08-01) -
Preclinical Toxicity and Safety of MM-129—First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer
by: Justyna Magdalena Hermanowicz, et al.
Published: (2021-08-01) -
General Synthesis of 1-Aryl-6-azaisocytosines and Their Utilization for the Preparation of Related Condensed 1,2,4-Triazines
by: František Zálešák, et al.
Published: (2019-10-01) -
Synthesis and spectral properties of novel thiadiazolotriazinone derivatives
by: Gürbüz Demet, et al.
Published: (2012-01-01)